Status:
COMPLETED
Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Influenza, Human
Eligibility:
All Genders
18-50 years
Phase:
EARLY_PHASE1
Brief Summary
As yet the investigators do not understand if there are biomarkers of immune protection after the Flumist or Live Attenuated Flu Vaccine (LAIV). Here the investigators test the hypothesis that the T-b...
Detailed Description
Previously (1) the investigators established that a fluorochrome labeled reagent with the influenza antigen hemagglutinin accurately identified flu-specific B cells after inactivated influenza vaccina...
Eligibility Criteria
Inclusion
- Missed getting the flu vaccine in the last year
- No history of reactive airway disease
- No history of allergy to LAIV
- No history of allergy to IIV
- Self-identify as healthy without an immunocompromising condition defined as cancer, autoimmune disease, organ transplant or receipt of steroids.
Exclusion
- History of reactive airway disease
- History of allergy to LAIV or IIV
- Do not self-identify as healthy
Key Trial Info
Start Date :
November 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04080245
Start Date
November 15 2019
End Date
June 1 2025
Last Update
June 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294